E2F4 Cancer Research Results

E2F4, E2F Transcription Factor 4: Click to Expand ⟱
Source:
Type:

E2F4 - E2F Transcription Factor 4

Type: Transcription factor / cell-cycle regulator

Function: E2F4 is a member of the E2F transcription-factor family that regulates genes involved in cell-cycle progression, DNA replication, differentiation, and quiescence. E2F4 frequently forms repressive complexes with RB-family proteins including p107/RBL1 and p130/RBL2 and is an important component of the DREAM complex that suppresses cell-cycle gene expression in quiescent cells.

Cancer: ↓ Typically reduced or functionally impaired as a cell-cycle repressor. Loss of E2F4-mediated transcriptional repression can promote inappropriate expression of S-phase and proliferation-associated genes. However, E2F4 can show context-dependent oncogenic activity in some tumors.

.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
7507- FA,    Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3
Dose↝, ATR↑, ATM↑, P21↑, p27/CDKN1B↑, E2F4↑, RB1↑, TP53↑, cycD1/CCND1↓, CDK2↓, CDK4↓, CDK6↓, TumCP↓, Casp1↑, Casp2↑, Casp8↑, Fas↑, TRADD↑, Bcl-2↓, XIAP↓, TumCCA↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

E2F4↑, 1,   TRADD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Bcl-2↓, 1,   Casp1↑, 1,   Casp2↑, 1,   Casp8↑, 1,   Fas↑, 1,   p27/CDKN1B↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   ATR↑, 1,   TP53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   RB1↑, 1,   TumCCA↑, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

TP53↑, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: E2F4, E2F Transcription Factor 4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1653  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page